Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

The availability of early-acting cytokines could allow the establishment of new approaches to chemical marrow purging. It was the aim of the present study to investigate the capability of recombinant human stem cell factor (SCF) in combination with other growth factors to support the in vitro growth of mafosfamide-treated progenitor cells such as mixed colony forming units (CFU-GEMM), erythroid burst forming units (BFU-E) and granulocyte-macrophage CFU (CFU-GM). When marrow cells were incubated (30 min, 37°C) with increasing doses of mafosfamide (30–120 m̈g/ml) a statistically significant (p ≤ .05), dose-dependent suppression of colony growth was observed. Addition of SCF (50 ng/ml) to marrow cultures stimulated with the standard mixture of growth factors (interleukin 3 or IL-3, granulocyte-macrophage colony stimulating factor or GM-CSF, and erythropoietin or Epo) significantly increased the mean (±SD) concentration of mafosfamide inducing 95% inhibition of CFU-GM (106 ± 17 versus 130 ± 29, p ≤ .0005), but not granulocyte/erythroid/macrophage/megakaryocyte CFU (CFU-GEMM) (85 ± 4 versus 90 ± 1, p ≤ .1) and BFU-E (90 ± 5 versus 92 ± 5, p ≤ .1). SCF induces a dose-dependent, statistically significant enhancement of colony formation by CD34+, mafosfamide-treated cells. As shown by single colony transfer experiments, mafosfamide-resistant clones promoted by SCF have a significantly higher replating capacity as compared with mafosfamide-resistant clones grown without SCF. In conclusion, SCF-enhanced proliferation of mafosfamide-treated, CD34-enriched progenitor cells further confirm that SCF is an early-acting cytokine that preferentially stimulates the growth of immature hematopoietic progenitors. These data might have relevant implications not only in view of “hyper-purging strategies,” but also for the clinical management of patients undergoing autologous bone marrow transplant (ABMT).

SCF, ABMT, Marrow Purging, Mafosfamide, Growth factors, Progenitor cells
This content is only available as a PDF.
© 1993 AlphaMed Press
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Issue Section:
Presentations
You do not currently have access to this article.
Download all slides